Prostate Cancer

Fluoroquinolones May Be Unwarranted for High PSA

Fluoroquinolones May Be Unwarranted for High PSA

By

PSA level declined by an average of 0.68 ng/mL in the treatment group.

Aminosalicylates Cut PCa Risk in Men with IBD

Aminosalicylates Cut PCa Risk in Men with IBD

By

Researchers found an adjusted 68% decreased risk of prostate cancer in men with IBD who used aminosalicylate.

Psychotherapy-PDE5 Inhibitor Combo Helps Post-RP Erectile Function

Psychotherapy-PDE5 Inhibitor Combo Helps Post-RP Erectile Function

By

An early, integrated approach led to less deterioration of erectile function after surgery.

Fatty Foods Possibly Contribute to Prostate Cancer Aggressiveness

Fatty Foods Possibly Contribute to Prostate Cancer Aggressiveness

Researchers also suggests that statins may help counteract harmful effect of fatty foods.

Polymer-Delivered Leuprolide Achieves Castration-Level Testosterone

Polymer-Delivered Leuprolide Achieves Castration-Level Testosterone

By

Testosterone levels of 20 ng/dL or less were achieved and maintained by more than 90% of men with advanced prostate cancer.

Better Prostate Cancer Survival With Low-Dose Aspirin?

Better Prostate Cancer Survival With Low-Dose Aspirin?

Improved odds seen for patients with colon, prostate, or breast tumors, but research isn't definitive.

Possible Biomarkers Identified for PCa Patients Treated With SBRT

Possible Biomarkers Identified for PCa Patients Treated With SBRT

Molecular pathways identified that may serve as potential biomarkers in prostate cancer treated with stereotactic body radiation therapy (SBRT).

Regular Exercise Before PCa Diagnosis May Increase Survival

Regular Exercise Before PCa Diagnosis May Increase Survival

Researchers found that men who exercised the most had the best outcomes.

Metformin Ups Anti-Cancer Activity of Abiraterone, Enzalutamide

Metformin Ups Anti-Cancer Activity of Abiraterone, Enzalutamide

Metformin, a widely used oral anti-diabetic drug, enhanced the anti-prostate cancer activity of abiraterone and enzalutamide.

Prostate Cancer Mortality Declined Along With Cigarette Smoking

Prostate Cancer Mortality Declined Along With Cigarette Smoking

By

Fewer prostate cancer deaths may be yet another benefit of smoking cessation.

Multiple Comorbidities Predict Higher-Risk Prostate Cancer

Multiple Comorbidities Predict Higher-Risk Prostate Cancer

By

Prostate cancer patients with 2 or more comorbid diseases are more likely to have their cancer upgraded and up staged at RP.

ADT for Prostate Cancer Linked to Depression

ADT for Prostate Cancer Linked to Depression

Researchers find 23% increased risk compared to men who received other treatments.

Optimal PSA Nadir After Prostate Cryoablation Identified

Optimal PSA Nadir After Prostate Cryoablation Identified

By

A PSA nadir below 0.4 ng/mL offers the best long-term biochemical progression-free survival, study shows.

Iodine-125 Interstitial Implant Possible for Low-risk Prostate Cancer

Iodine-125 Interstitial Implant Possible for Low-risk Prostate Cancer

Findings based on 10-year follow-up of localized prostate cancer patients.

Prostate Cancer Metastasis Risk Higher in Some AS Patients

Prostate Cancer Metastasis Risk Higher in Some AS Patients

By

Study points to a need for caution in using active surveillance for men with Gleason 7 disease.

Carb Consumption Linked to Breast, Prostate Cancers

Carb Consumption Linked to Breast, Prostate Cancers

Prostate and breast cancers were elevated in patients who consumed a diet high in glycemic load and sugary drinks.

Clinician Training Influences PSA Screening in Senior Veterans

Clinician Training Influences PSA Screening in Senior Veterans

Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.

Prostate Biopsy Rates Fall Following Guideline Updates

Prostate Biopsy Rates Fall Following Guideline Updates

By

The proportion of biopsied men who have complications from the procedure rose from 14% to 18% from 2005 to 2014.

Bevacizumab Plus ADT May Up Survival in Recurrent Prostate Cancer

Bevacizumab Plus ADT May Up Survival in Recurrent Prostate Cancer

Adding bevacizumab to androgen deprivation therapy (ADT) resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer.

Study: Shorter Radiotherapy Schedule OK for Localized Prostate Cancer

Study: Shorter Radiotherapy Schedule OK for Localized Prostate Cancer

By

Disease-free survival rates were similar for groups receiving 8.2 weeks of conventional versus 5.6 weeks of hypofractionated radiotherapy.

Saturation Prostate Biopsy Not Better

Saturation Prostate Biopsy Not Better

By

Detection of high Gleason grade tumors is not significantly improved versus standard 12-core biopsy.

More Radiation May Not Improve Survival in Localized Prostate Cancer

More Radiation May Not Improve Survival in Localized Prostate Cancer

By

Findings imply that freedom from biochemical failure is a poor proxy for outcomes for radiotherapy patients.

Advanced Prostate Cancer May Respond to Bicalutamide-Everolimus Combo

Advanced Prostate Cancer May Respond to Bicalutamide-Everolimus Combo

By

In a small study, 75% of men with castration-resistant prostate cancer experienced a 30% or greater decline in PSA from baseline.

Prostate Cancer Risk Lower in Men Who Ejaculate More

Prostate Cancer Risk Lower in Men Who Ejaculate More

By

The protective effect is strongest for low-risk disease.

Only Conservative PSA Testing is Cost-Effective

Only Conservative PSA Testing is Cost-Effective

This includes less frequent screening and more restrictive biopsy referral criteria.

RP Linked With Favorable Outcomes in PCa Patients Considered Low Risk

RP Linked With Favorable Outcomes in PCa Patients Considered Low Risk

By

Men with low-risk prostate cancer who undergo open or robot-assisted radical prostatectomy may have favorable oncological outcomes.

PCa Patients Treated at High-Volume Radiation Centers Fare Better

PCa Patients Treated at High-Volume Radiation Centers Fare Better

By

Each increment of 100 patients treated was associated with a 3% increase in overall survival.

Radioligand Therapy With 177Lu-PSMA-I&T Appears Safe in mCRPC

Radioligand Therapy With 177Lu-PSMA-I&T Appears Safe in mCRPC

Rigoligand therapy with a beta-emitting 177Lu-PSMA-I&T appeared to be safe and active in heavily treated prostate cancer.

Questions Remain on Late Toxicity With Hypofractionated RT in PCa

Questions Remain on Late Toxicity With Hypofractionated RT in PCa

Cumulative late genitourinary and gastrointestinal toxicity was more common with hypofractionated radiotherapy in patients with prostate cancer.

Novel Approaches to Using Radium-223

Novel Approaches to Using Radium-223

By

An interview with Neal Shore, MD

Sign Up for Free e-newsletters